Premium
Inhaled Nitric Oxide During Extracorporeal Membrane Oxygenation for the Treatment of Severe Persistent Pulmonary Hypertension of the Newborn
Author(s) -
Müller Werner,
Kachel Walter,
Lasch Peter,
Varnholt Verena,
König Stephan
Publication year - 1996
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1111/j.1525-1594.1996.tb04420.x
Subject(s) - extracorporeal membrane oxygenation , medicine , persistent pulmonary hypertension , inhalation , oxygenation , anesthesia , nitric oxide , pulmonary hypertension , oxygenation index , blood pressure , adverse effect , respiratory failure , extracorporeal
Inhaled nitric oxide (NO) as a complementary treatment was studied in 10 neonates during extracorporeal membrane oxygenation (ECMO) therapy of various persistent pulmonary hypertension of the newborn (PPHN)‐associated diseases. At individually different levels of inhaled NO (20–80 ppm), the mean Pao 2 increased by 59.7% in 6 responders, but it remained unchanged in 4 nonresponders. Adverse side effects of the NO inhalation were tolerable. It was associated with a reversible decrease of the mean arterial blood pressure in 1 patient. During prolonged NO inhalation, the methemo‐globin (met‐Hb) level increased to 0.9‐4.6% in 6 patients. Based on these preliminary results, we conclude that inhaled NO during ECMO can improve oxygenation in some PPHN patients. Further studies with control groups are needed to determine whether inhaled NO can shorten ECMO treatment or improve the rate of survival among PPHN patients.